231 related articles for article (PubMed ID: 23722548)
1. Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.
Zhou H; Hittelman WN; Yagita H; Cheung LH; Martin SS; Winkles JA; Rosenblum MG
Cancer Res; 2013 Jul; 73(14):4439-50. PubMed ID: 23722548
[TBL] [Abstract][Full Text] [Related]
2. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.
Zhou H; Ekmekcioglu S; Marks JW; Mohamedali KA; Asrani K; Phillips KK; Brown SA; Cheng E; Weiss MB; Hittelman WN; Tran NL; Yagita H; Winkles JA; Rosenblum MG
J Invest Dermatol; 2013 Apr; 133(4):1052-62. PubMed ID: 23190886
[TBL] [Abstract][Full Text] [Related]
3. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
4. Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.
Zhou H; Marks JW; Hittelman WN; Yagita H; Cheung LH; Rosenblum MG; Winkles JA
Mol Cancer Ther; 2011 Jul; 10(7):1276-88. PubMed ID: 21586630
[TBL] [Abstract][Full Text] [Related]
5. Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.
Zhou H; Mohamedali KA; Gonzalez-Angulo AM; Cao Y; Migliorini M; Cheung LH; LoBello J; Lei X; Qi Y; Hittelman WN; Winkles JA; Tran NL; Rosenblum MG
Mol Cancer Ther; 2014 Nov; 13(11):2688-705. PubMed ID: 25239934
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.
Salzmann S; Seher A; Trebing J; Weisenberger D; Rosenthal A; Siegmund D; Wajant H
J Biol Chem; 2013 May; 288(19):13455-66. PubMed ID: 23532848
[TBL] [Abstract][Full Text] [Related]
7. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.
Huang J; Wang S; Lyu H; Cai B; Yang X; Wang J; Liu B
Mol Cancer; 2013 Nov; 12(1):134. PubMed ID: 24215614
[TBL] [Abstract][Full Text] [Related]
8. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity.
Willis AL; Tran NL; Chatigny JM; Charlton N; Vu H; Brown SA; Black MA; McDonough WS; Fortin SP; Niska JR; Winkles JA; Cunliffe HE
Mol Cancer Res; 2008 May; 6(5):725-34. PubMed ID: 18505918
[TBL] [Abstract][Full Text] [Related]
9. Development of an Fn14 agonistic antibody as an anti-tumor agent.
Michaelson JS; Amatucci A; Kelly R; Su L; Garber E; Day ES; Berquist L; Cho S; Li Y; Parr M; Wille L; Schneider P; Wortham K; Burkly LC; Hsu YM; Joseph IB
MAbs; 2011; 3(4):362-75. PubMed ID: 21697654
[TBL] [Abstract][Full Text] [Related]
10. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
Garrett JT; Sutton CR; Kurupi R; Bialucha CU; Ettenberg SA; Collins SD; Sheng Q; Wallweber J; Defazio-Eli L; Arteaga CL
Cancer Res; 2013 Oct; 73(19):6013-23. PubMed ID: 23918797
[TBL] [Abstract][Full Text] [Related]
11. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
12. The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.
Michaelson JS; Kelly R; Yang L; Zhang X; Wortham K; Joseph IB
Cancer Biol Ther; 2012 Jul; 13(9):812-21. PubMed ID: 22669574
[TBL] [Abstract][Full Text] [Related]
13. Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb.
Chao DT; Su M; Tanlimco S; Sho M; Choi D; Fox M; Ye S; Hsi ED; Durkin L; Yin J; Zhang Y; Kim H; Starling GC; Culp PA
J Cancer Res Clin Oncol; 2013 Feb; 139(2):315-25. PubMed ID: 23073510
[TBL] [Abstract][Full Text] [Related]
14. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
15. Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.
Roos A; Dhruv HD; Mathews IT; Inge LJ; Tuncali S; Hartman LK; Chow D; Millard N; Yin HH; Kloss J; Loftus JC; Winkles JA; Berens ME; Tran NL
Oncotarget; 2017 Feb; 8(7):12234-12246. PubMed ID: 28103571
[TBL] [Abstract][Full Text] [Related]
16. The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.
Asrani K; Keri RA; Galisteo R; Brown SA; Morgan SJ; Ghosh A; Tran NL; Winkles JA
Mol Cancer Res; 2013 Apr; 11(4):393-404. PubMed ID: 23378579
[TBL] [Abstract][Full Text] [Related]
17. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor.
Chen C; Zhang Y; Zhang Y; Li J; Tsao SW; Zhang MY
Mol Cancer Ther; 2014 Jan; 13(1):90-100. PubMed ID: 24227890
[TBL] [Abstract][Full Text] [Related]
18. The TWEAK Receptor Fn14 Is an Src-Inducible Protein and a Positive Regulator of Src-Driven Cell Invasion.
Cheng E; Whitsett TG; Tran NL; Winkles JA
Mol Cancer Res; 2015 Mar; 13(3):575-83. PubMed ID: 25392346
[TBL] [Abstract][Full Text] [Related]
19. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
Garrett JT; Sutton CR; Kuba MG; Cook RS; Arteaga CL
Clin Cancer Res; 2013 Feb; 19(3):610-9. PubMed ID: 23224399
[TBL] [Abstract][Full Text] [Related]
20. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.
Raina D; Uchida Y; Kharbanda A; Rajabi H; Panchamoorthy G; Jin C; Kharbanda S; Scaltriti M; Baselga J; Kufe D
Oncogene; 2014 Jun; 33(26):3422-31. PubMed ID: 23912457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]